Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cutaneous Melanoma: early-phase trial registry
16 of 31 indexed Cutaneous Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 16 currently recruiting · #495 of 28,707 conditions by registered trial count
Cutaneous Melanoma: 31 US clinical trials tracked, 16 recruiting.
Cutaneous Melanoma is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 2 of these trials.
Enrollment posture brief
Registry condition cutaneous-melanoma
OPEN 16 | RECR 52% | LATE 0 | EARLY 24 | RANK #495 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Kidney Transplant (52% recruiting · 31 trials)
Cutaneous Melanoma lists 16 open slots (52% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cutaneous Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cutaneous Melanoma is recruiting above its size-band peers.
16 of 31 indexed trials (51.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cutaneous Melanoma trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 2 of 31 trials (6.5%). 30 distinct sponsors appear on at least one study for this condition label.
-
Typical Cutaneous Melanoma enrolment sits around 100 participants.
Median target enrolment is 100 among the 31 trials that report a genuine target (sentinel values excluded). 14 of those (45.2%) plan for fewer than 100 participants.
-
Cutaneous Melanoma research is mostly interventional.
26 interventional and 5 observational studies make up this index (83.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
M.D. Anderson Cancer Center
NCT04778449
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Guardant Health
NCT05059444
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Mohamed Abdel-Rahman
NCT04792463
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT05669430
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation
NCT05824975
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
NCT03947385
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
University of California, San Francisco
NCT07148245
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Krystal Biotech
NCT05970497
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse
NCT06090266
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience
NCT05267626
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics
NCT06624644
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ohio State University Comprehensive Cancer Center
NCT06223659
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
University of Utah
NCT06194929
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
University of Louisville
NCT03842943
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
AdventHealth Translational Research Institute
NCT06008977
ACTengine® IMA203 Combined With mRNA-4203
Immatics US
NCT06946225
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Replimune
NCT03767348
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group
NCT03611868
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT05544929
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
OHSU Knight Cancer Institute
NCT03699995
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05571839
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05358938
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
NCT04020809
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05628883
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Dana-Farber Cancer Institute
NCT03929029
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
NCT06984328
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT02791334
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
Memorial Sloan Kettering Cancer Center
NCT03843593
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
NCT00679289
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
NCT04551352
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Cutaneous Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cutaneous Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cutaneous Melanoma page
31 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Cutaneous Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Cutaneous Melanoma trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cutaneous Melanoma condition card totals 31 registered trials; most-linked intervention Medical Chart Review; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.